Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study

Rakha, E A; Tan, P H; Varga, Z; Tse, G M; Shaaban, A M; Climent, F; van Deurzen, C H M; Purnell, D; Dodwell, D; Chan, T; Ellis, I O
January 2015
British Journal of Cancer;1/20/2015, Vol. 112 Issue 2, p283
Academic Journal
Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small case series or population-based reports. This study aimed to assess the clinicopathological features and outcome of MBC identified through an international multicentre collaboration.Methods:A large international multicentre series of MBC (no=405) with histological confirmation and follow-up information has been included in this study. The prognostic value of different variables and outcome has been assessed and compared with grade, nodal status and ER/HER2 receptor-matched ductal/NST breast carcinoma.Results:The outcome of MBC diagnosed in Asian countries was more favourable than those in Western countries. The outcome of MBC is not different from matched ductal/NST carcinoma but the performance of the established prognostic variables in MBC is different. Lymph node stage, lymphovascular invasion and histologic subtype are associated with outcome but tumour size and grade are not. Chemotherapy was associated with longer survival, although this effect was limited to early-stage disease. In this study no association between radiotherapy and outcome was identified. Multivariate analysis of MBC shows that histologic subtype is an independent prognostic feature.Conclusions:This study suggests that MBC is a heterogeneous disease. Although the outcome of MBC is not different to matched conventional ductal/NST breast carcinoma, its behaviour is dependent on the particular subtype with spindle cell carcinoma in particular has an aggressive biological behaviour. Management of patients with MBC should be based on validated prognostic variables.


Related Articles

  • Clinicopathological study of centrally necrotizing carcinoma of the breast. Yanling Zhang; Yurong Ou; Donghong Yu; Xiang Yong; Xiaoli Wang; Bo Zhu; Qiong Zhang; Lei Zhou; Zhaogen Cai; Zenong Cheng // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Centrally necrotizing carcinoma of the breast (CNC) represents a newly-identified subset of breast cancer. The clinical and pathological characteristics of this breast cancer subtype are not yet completely understood. Methods: We assessed the clinicopathological characteristics of 73...

  • Young breast cancer: A single center experience. Gogia, A.; Raina, V.; Deo, S. V. S.; Shukla, N. K.; Mohanti, B. K. // Indian Journal of Cancer;Oct-Dec2014, Vol. 51 Issue 4, p604 

    Background: Breast cancer in women aged less than 35 years is uncommon and accounts for 1-2% of all breast cancer in the West. There is a paucity of data on young breast cancer from India. The aim of this study was to analyze the clinical, pathological, prognostic factors and...

  • The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China. Wu, Haibo; Wang, Wei; Du, Jun; Li, Hong; Wang, Huogang; Huang, Liangliang; Xiang, Hang; Xie, Jing; Liu, Xiaoli; Li, Heng; Lin, Wenchu // Cancer Management & Research;Feb2019, Vol. 11, p1473 

    Purpose: The mutation status and prognostic value of PIK3CA in breast cancer were widely investigated, which showed significant difference among the patients from vast areas around the world. In this study, the frequency, distribution, bias, and burden of PIK3CA mutations and their relationships...

  • Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. Naoki Aomatsu; Masakazu Yashiro; Shinichiro Kashiwagi; Hidemi Kawajiri; Tsutomu Takashima; Masahiko Ohsawa; Kenichi Wakasa; Kosei Hirakawa // BMC Cancer;2014, Vol. 14 Issue 1, p131 

    Background Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating NAC. One of the parameters potentially compromising such chemosensitivity...

  • Vimentin as a poor prognostic factor for triple-negative breast cancer. Yamashita, Nami; Tokunaga, Eriko; Kitao, Hiroyuki; Hisamatsu, Yuichi; Taketani, Kenji; Akiyoshi, Sayuri; Okada, Satoko; Aishima, Shinichi; Morita, Masaru; Maehara, Yoshihiko // Journal of Cancer Research & Clinical Oncology;May2013, Vol. 139 Issue 5, p739 

    Purpose: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a highly heterogeneous disease. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal...

  • Clinicopathologic characteristics and survival of male breast cancer. Liu, Dongying; Xie, Guangru; Chen, Ming // International Journal of Clinical Oncology;Apr2014, Vol. 19 Issue 2, p280 

    Backgrounds: Male breast cancer (MBC) is a rare disease and accounts for <1 % of all breast cancers. Methods: We retrospectively analyzed clinicopathologic characteristics and prognosis of MBC patients who were diagnosed in our hospital between March 2002 and March 2012. Results: The median age...

  • Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Petrelli, F.; Barni, S. // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2586 

    High levels of human epidermal growth receptor 2 (HER2) expression are associated with recurrence and death in breast cancer (BC) patients. We have performed a systematic review and meta-analysis in order to evaluate the prognosis for HER2+ pT1a-bN0M0 BC patients. A search of PubMed and Embase...

  • Biomarkers characterization of circulating tumour cells in breast cancer patients.  // Breast Cancer Research;2012, Vol. 14 Issue 1, pR71 

    The article focuses on a study that analyzes the expression of epidermal growth factor receptor (EGFR) in circulating tumor cells (CTCs) of patients with breast cancer. The researchers objective was to distinguish the set of biomarkers in CTCs and correlate it with clinical-pathological...

  • Serum Caspase-3 and Caspase-7 as Predictive Factors of Response in Locally Advanced and Metastatic Breast Carcinoma. Hammoud, Hayma; Saleh, Jumana; Bachour, Marroan; Salamoon, Maher // Journal of Cancer Therapy;May2014, Vol. 5 Issue 6, p584 

    Introduction: Breast cancer is the most common cancer in women and the second most frequent cause of cancer death. Several factors affect response to chemotherapy including nodal status, hormonal status and human epidermal growth factor receptor (Her-2). Aim of Study: The study is aiming at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics